Orvepitant
Orvepitant[edit]
Orvepitant is a neurokinin-1 receptor antagonist that has been investigated for its potential therapeutic effects in various conditions, including chronic cough, depression, and post-traumatic stress disorder (PTSD). It is a small molecule drug that works by blocking the action of substance P, a neuropeptide involved in the transmission of pain and other sensory signals.
Mechanism of Action[edit]
Orvepitant functions as an antagonist at the neurokinin-1 receptor (NK1R), which is a receptor for substance P. By inhibiting the binding of substance P to NK1R, orvepitant can modulate the central nervous system's response to stress and pain. This mechanism is thought to underlie its potential therapeutic effects in conditions like depression and anxiety disorders.
Clinical Applications[edit]
Chronic Cough[edit]
Orvepitant has been studied for its efficacy in treating chronic cough, a condition characterized by a persistent cough lasting more than eight weeks. The drug's ability to block substance P is believed to reduce the cough reflex, providing relief to patients.
Depression[edit]
In the context of depression, orvepitant's role as a neurokinin-1 receptor antagonist may help alleviate symptoms by modulating the neurotransmitter systems involved in mood regulation. Studies have explored its use as an adjunctive treatment to enhance the effects of traditional antidepressants.
Post-Traumatic Stress Disorder[edit]
Orvepitant has also been investigated for its potential benefits in treating post-traumatic stress disorder (PTSD). By dampening the stress response mediated by substance P, orvepitant may help reduce the severity of PTSD symptoms.
Pharmacokinetics[edit]
Orvepitant is administered orally and undergoes hepatic metabolism. Its pharmacokinetic profile includes a moderate half-life, allowing for once-daily dosing in clinical settings. The drug is primarily excreted via the renal and biliary systems.
Safety and Tolerability[edit]
In clinical trials, orvepitant has been generally well-tolerated. Common side effects include nausea, dizziness, and headache. Serious adverse effects are rare but may include allergic reactions and liver enzyme elevations.
Research and Development[edit]
Orvepitant is still under investigation, with ongoing studies aimed at better understanding its efficacy and safety profile across different patient populations. Its development reflects a broader interest in targeting the neurokinin-1 receptor for various neuropsychiatric disorders.
Related Pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
